

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



Whelan, KT; Pathan, AA; Sander, CR; Fletcher, HA; Poulton, I; Alder, NC; Hill, AV; McShane, H (2009) Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A. PLoS One, 4 (6). e5934. ISSN 1932-6203 DOI: <https://doi.org/10.1371/journal.pone.0005934>

Downloaded from: <http://researchonline.lshtm.ac.uk/1217141/>

DOI: [10.1371/journal.pone.0005934](https://doi.org/10.1371/journal.pone.0005934)

#### Usage Guidelines

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact [researchonline@lshtm.ac.uk](mailto:researchonline@lshtm.ac.uk).

Available under license: <http://creativecommons.org/licenses/by/2.5/>

# University of Oxford



## Clinical Trial Protocol

**Study Reference: 006**

A Phase I study of the safety and immunogenicity of BCG (Bacille Calmette-Guerin) vaccine delivered intradermally by a needle injection in healthy volunteers who have previously received BCG.

**Version 2; 22.6.2004**

**CONFIDENTIAL**

## 1. INTRODUCTION AND BACKGROUND

### 1.1 The need for new vaccine against tuberculosis

Tuberculosis (TB) kills about three million people annually. It is estimated that one third of the world's population are latently infected with *Mycobacterium tuberculosis* (*M.tb*). Multi-drug resistant strains of *M.tb*, and co-infection with *M.tb* and HIV present major new challenges. The currently available vaccine, *M. bovis* BCG, is largely ineffective at protecting against adult pulmonary disease in endemic areas and it is widely agreed that a new more effective tuberculosis vaccine is a major global public health priority<sup>1</sup>. However, it may be unethical and impractical to test and deploy a vaccine strategy that does not include BCG, as BCG does confer worthwhile protection against TB meningitis and leprosy. An immunisation strategy that includes BCG is also attractive because the populations in which this vaccine candidate will need to be tested will already have been immunised with BCG.

*M.tb* is an intracellular organism. CD4+ Th1-type cellular responses are essential for protection and there is increasing evidence from animal and human studies that CD8+ T cells also play a protective role<sup>2</sup>. However, it has generally been difficult to induce strong cellular immune responses in humans using subunit vaccines. DNA vaccines induce both CD4+ and CD8+ T cells and thus offer a potential new approach to a TB vaccine. DNA vaccines encoding various antigens from *M. tuberculosis* have been evaluated in the murine model, and to date no DNA vaccine alone has been shown to be superior to BCG<sup>3,4</sup>.

A heterologous prime-boost immunisation strategy involves giving two different vaccines, each encoding the same antigen, several weeks apart. Such regimes are extremely effective at inducing a cellular immune response. Using a DNA- prime/MVA-boost immunisation strategy induces high levels of CD8+ T cells in animal models of malaria and HIV<sup>5,6</sup>, and high levels of both CD4+ and CD8+ T cells in animal models of TB<sup>7</sup>. BCG immunisation alone induces only CD4+ T cells in mice. A prime-boost strategy using BCG as the prime and a recombinant MVA encoding an antigen from *M.tb* that is also present in BCG (antigen 85A: 'MVA85A') as the boost, induces much higher levels of CD4+ T cells than BCG or MVA85A alone. In addition, this regime generates specific CD8+ T cells that are undetectable following immunisation with BCG alone.

### 1.2 Recombinant viruses as vaccines.

Recombinant viruses used alone have for some years represented a promising vaccine delivery system, particularly for inducing cellular immune responses<sup>8</sup>. The recombinant virus encodes the immunising protein or peptide. Immunisation by a recombinant virus vaccine occurs when host cells take up and express the inoculated attenuated virus encoding a protective antigen<sup>9</sup>. The expressed protein often has the native conformation, glycosylation, and other post-translational modifications that occur during natural infection. Recombinant viral vaccines may elicit both antibody and cytotoxic T-lymphocyte responses<sup>10</sup>, which persist without further immunisations. Many viruses have been investigated as potential recombinant vaccines. The successful worldwide eradication of smallpox via vaccination with live vaccinia virus highlighted vaccinia as a candidate for recombinant use<sup>11,12,13</sup>. The recognition in recent years that non-replicating strains of poxvirus such as MVA and avipox vectors can be more immunogenic than traditional replicating vaccinia strains has enhanced the attractiveness of this approach. MVA (modified

vaccinia virus Ankara) is a strain of vaccinia virus which has been passaged more than 570 times through avian cells, is replication incompetent in human cell lines and has a good safety record. It has been administered to more than 120,000 vaccinees as part of the smallpox eradication programme, with no adverse effects, despite the deliberate vaccination of high risk groups<sup>14,15</sup>. This safety in man is consistent with the avirulence of MVA in animal models<sup>16</sup>. MVA has six major genomic deletions compared to the parental genome severely compromising its ability to replicate in mammalian cells<sup>17</sup>. Viral replication is blocked late during infection of cells but importantly viral and recombinant protein synthesis is unimpaired even during this abortive infection<sup>18</sup>. Replication-deficient recombinant MVA has been seen as an exceptionally safe viral vector<sup>19,20</sup>. When tested in animal model studies recombinant MVAs have been shown to be avirulent, yet protectively immunogenic as vaccines against viral diseases and cancer<sup>6,21,22,23,24</sup>. The most useful data on the safety and efficacy of various doses of a recombinant MVA vaccine comes from clinical trial data with a recombinant MVA expressing a number of CTL epitopes from *Plasmodium falciparum* pre-erythrocytic antigens fused to a complete pre-erythrocytic stage antigen, Thrombospondin Related Adhesion Protein (TRAP). These trials have given a total of 169 immunisations with this recombinant MVA, to 49 UK vaccinees 38 Gambian vaccinees (20 of whom were children aged 1-5). 6 doses of  $1 \times 10^7$  pfu, 139 doses of  $5 \times 10^7$  pfu, 6 doses of  $1 \times 10^8$  pfu and 18 doses of  $2.5 \times 10^8$  pfu have been administered, all without serious adverse effects.

### **1.3 Recombinant MVA encoding antigen 85A**

Secreted antigens from *M. tuberculosis* are released from actively metabolising bacteria, and are important targets in protective immunity<sup>25</sup>. Antigen 85A is a major secreted antigen from *M. tuberculosis* which forms part of the antigen 85 complex (A, B and C). This complex constitutes a major portion of the secreted proteins of both *M.tb* and BCG. It is involved in fibronectin binding within the cell wall and has mycolyltransferase activity<sup>26</sup>.

MVA85A induces both a CD4+ and a CD8+ epitope when used to immunise mice. When mice are primed with BCG and then given MVA85A as a boost, the levels of CD4+ and CD8+ T cells induced are higher than with either BCG or MVA85A alone.

We are evaluating the safety and immunogenicity of the following 3 groups:

1. BCG alone
2. MVA85A alone
3. BCG prime-MVA85A boost

BCG-BCG provides a control group for BCG-MVA85A. Many countries have a tradition of repeated BCG vaccination and the criteria for revaccination differ between countries<sup>27</sup>.

## **2. DESCRIPTION OF THE STUDY**

### **2.1 Study Objective**

To assess the safety and immunogenicity of BCG delivered intradermally into the deltoid region in volunteers who have received BCG 10 - 20 years previously.

## **2.2 Selection of volunteers**

Volunteers for the study will be recruited through advertisements. Each volunteer will have received an information sheet concerning the study and will have agreed to participate in writing. Volunteers will be given at least 48 hours between reading the information leaflet and agreeing to participate. Female volunteers will be told of the theoretical risk of congenital anomaly should they become pregnant during the study and only those who undertake to take precautions to avoid pregnancy during the study period will be eligible. Volunteers will give signed consent for their GP's to be notified about their participation in the trial. The GP will be faxed a letter on the day of screening and asked to reply if they know of a reason why the volunteer should not take part. The signed consent form will also be faxed with the letter.

## **2.3 Screening**

Volunteers will be asked to sign the informed consent form for screening. The following will be performed:

- Medical history and examination
- Laboratory evaluations – including clinical chemistry, haematology, HLA typing, anti-HBV antibodies, anti-HCV antibodies, anti-HIV antibodies
- Heaf test – to exclude prior exposure to TB
- Urinalysis and urine pregnancy test if female

## **2.4 Inclusion Criteria**

- Healthy adult aged 18-55 years.
- Normal medical history and physical examination.
- Normal urine dipstick, blood count, liver enzymes, and creatinine.

## **2.5 Exclusion Criteria**

- a. Exposure to TB at any point. A positive ESAT6/CFP10 Elispot response (defined as greater than 5 spots/well above background and at least double the background response).
- b. Clinically significant history of skin disorder (eczema, psoriasis, etc.), allergy, immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurological illness, psychiatric disorder, drug or alcohol abuse.
- c. Oral or systemic steroid medication or the use of immunosuppressive agents.
- d. Positive HIV antibody test, HCV antibody test or positive HBV serology except post-vaccination.
- e. Heaf test greater than Grade II
- f. Confirmed pregnancy

## **2.6 Withdrawal Criteria**

- a. Withdrawal of consent by subject for any reason

- b. Loss to follow-up
- c. Non-compliance with study procedures
- d. Protocol violation
- e. Serious adverse event (as defined in Appendix 3)
- f. Any other reason at discretion of the Principal Investigator
- g. Confirmed pregnancy during study period

## **2.7 Immunisation**

On Day 0, subjects will receive a single intradermal injection of 0.1ml BCG over the deltoid muscle. Vital signs will be monitored at 30 and 60 minutes post-immunisation. Local reactions at the site of administration will be evaluated at 60 minutes.

A photograph of the injection site may be taken at 48 hours (with written consent). The injection site will be reviewed 7 days after each immunization.

Blood will be taken at the following time points: At the screening visit\*, prior to the vaccination, 1 week after the first vaccination\*, 2 weeks, 4 weeks, 8 weeks, 12 weeks\* and 24 weeks after the vaccination. Up to 55 mls will be taken at any one time with the total being no more than 500 mls over the study period. \*Samples taken on these dates will be tested for full blood count and biochemical screen. Immunological assays will be performed at all time points to determine vaccine immunogenicity. A pregnancy test will be performed prior to vaccination for female volunteers. Peripheral blood mononuclear cells will be prepared for cellular immunological assays to be performed without or following cryopreservation. Other serological measures of immune response, i.e. antibody titres, will be assayed on frozen plasma samples.

All blood tests will be taken within 1-3 days of the due date as described in the schedule above.

At the 24 week timepoint, a Heaf test will be repeated in order to document the change (if any) in Heaf responsiveness after the second BCG vaccination.

## **2.8 Endpoints**

The occurrence and severity of local side-effects

The occurrence and severity of systemic side-effects

The induction of T cell responses (as measured by an interferon-gamma Elispot assay).

Proliferation assays and cytotoxic T cell assays will be performed on strong CD4+ and CD8+ responses respectively.

## **2.9 Adverse Events**

See Appendix 1.

## References

1. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F. Efficacy of BCG vaccine in the prevention of TB. Meta-analysis of the published literature. *J Am Med Assoc* 1994;271:698-702
2. Stenger S, Modlin RL. T cell mediated immunity to Mycobacterium TB. *Curr Op Micro* 1999; 2: 89-93
3. Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, Deck RR, DeWitt CM, Orme IM, Baldwin S, D'Souza C, Drowart A, Lozes E, Vandenbussche P, Van Vooren JP, Liu MA, Ulmer JB. Immunogenicity and protective efficacy of a TB DNA vaccine. *Nature Medicine* 1996;2:893-898
4. Tascon RE, Colston MJ, Ragno S, Stavropoulos E, Gregory D, Lowrie DB. Vaccination against tuberculosis by DNA injection. *Nature Medicine* 1996;2:888-892
5. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, Becker M, Sinden R, Smith GL, Hill AVS. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. *Nature Medicine* 1998;4:397-402
6. Hanke T, Samuel RV, Blanchard TJ, Neumann VC, Allen TM, Boyson JE, Sharpe SA, Cook N, Smith GL, Watkins DI, Cranage MP, McMichael AJ. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. *J Virol* 1999;73(9):7524-32
7. McShane H, Brookes R, Gilbert SC, Hill AVS. 2001. Enhanced immunogenicity of CD4+ T cell responses and protective efficacy of a DNA-MVA prime-boost vaccination regime in murine tuberculosis. *Infection & Immunity*. 69:681-686
8. Paoletti E. Applications of pox virus vectors to vaccination: an update. *Proc Natl Acad Sci USA* 1996;93:11349-11353.
9. Smith GL, Cheng KC, Moss B. Vaccinia virus: an expression vector for genes from parasites. *Parasitology* 1986;92 Suppl:S109-17
10. Rodrigues M, Li S, Murata K, Rodriguez D, Rodriguez JR, Bacik I, Bennink JR, Yewdell JW, Garcia-Sastre A, Nussenzweig RS, et al. Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. *J Immunol* 1994 Nov 15;153(10):4636-48
11. Mackett M, Smith G, Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. *Proc Natl Acad Sci USA* 1982; 79: 7415-7419.
12. Panicali D, Paoletti E. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. *Proc Natl Acad Sci USA* 1982; 79: 4927-4931.
13. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination and safety. *Proc Natl Acad Sci USA* 1996; 93: 11341-11348.
14. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, Holzner A. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain. *Dtsch Med Wochenschr* 1974 Nov 22;99(47):2386-92.
15. Mahnel H, Mayr A. Experiences with immunization against orthopox viruses of humans and animals using vaccine strain MVA. *Berl Munch Tierarztl Wochenschr* 1994 Aug;107(8):253-6.

16. Mayr A, Stickl H, Muller HK, Danner K, Singer H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. *Zentralbl Bakteriol [B]* 1978 Dec;167(5-6):375-90.
17. Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. *J Gen Virol* 1991 May;72 (Pt 5):1031-8.
18. Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. *Proc Natl Acad Sci U S A* 1992 Nov 15;89(22):10847-51.
19. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination and safety. *Proc Natl Acad Sci USA* 1996; 93: 11341-11348.
20. Sutter G, Moss B. Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus. *Dev Biol Stand* 1995;84:195-200.
21. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. *Vaccine* 1994 Aug;12(11):1032-40.
22. Hirsch VM, Fuerst TR, Sutter G, Carroll MW, Yang LC, Goldstein S, Piatak M Jr, Elkins WR, Alvord WG, Montefiori DC, Moss B, Lifson JD. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. *J Virol* 1996 Jun;70(6):3741-52.
23. Wyatt LS, Shors ST, Murphy BR, Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. *Vaccine* 1996 Oct;14(15):1451-8.
24. Carroll MW, Overwijk WW, Chamberlain RS, Rosenberg SA, Moss B, Restifo NP. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. *Vaccine* 1997 Mar;15(4):387-94.
25. Horwitz MA, Lee BW, Dillon BJ, Harth G. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of *Mycobacterium tuberculosis*. *Proc. Natl. Acad. Sci. U.S.A.* 92, 1530-1534.
26. Belisle JT et al. Role of the major antigen of mycobacterium TB in cell wall biogenesis. *Science* 1997;276:1420-1422
27. WHO (EPI). Immunisation schedules in the WHO European Region, 1995. *WHO Wkly Epidem Rec* 1995; 70 (31):221-227



# APPENDIX 1

## ADVERSE EVENTS

### *1. Definition and Grading Intensity of Adverse Events*

An adverse event is defined as any unintended change in the body structure (signs) or body function (symptoms), whether or not considered related to test product. During the entire study, subjects will be instructed to report all adverse events. All adverse events, whether volunteered, elicited or noted on physical examination, will be recorded throughout the study.

The severity of adverse events will be categorized as follows:

- MILD = Experience that is minor and does not cause significant discomfort to subject or change in activities of daily living (ADLs); subject is aware of symptoms but symptoms are easily tolerated.
- MODERATE = Experience is an inconvenience or concern to the subject and causes interference with ADLs but the subject is able to continue with ADLs.
- SEVERE = Experience significantly interferes with ADLs and the subject is incapacitated and/or unable to continue with ADLs.

### *2. Criteria for Determining Relationship to Test Product*

The Investigator will make a determination of the relationship of the adverse event to the test product. The relationship to test product of all adverse events will be classified according to the following guidelines:

- NOT RELATED = Data available to clearly identify an alternative cause of the reaction, e.g., hemorrhage due to mechanical injury.
- UNLIKELY
  - Reasonable temporal relation to vaccination, BUT
  - Unlabeled/unexpected reaction, AND
  - The reaction can be reasonably explained by other factors (such as interventions), AND
  - Negative de-challenge, if available, OR
  - No reasonable temporal relation to vaccination.
- POSSIBLE

- Reasonable temporal relation to vaccination, AND
- Labeled/expected reaction, OR
- Unlabeled/unexpected reaction, BUT
- Other factors could have caused or contributed to the reaction (such as subject's clinical state, concomitant therapy, and/or other interventions).
- PROBABLE
  - Reasonable temporal relation to vaccination, AND
  - Labeled/expected reaction, AND
  - The reaction cannot be reasonably explained by other factors (such as the subject's clinical state, concomitant therapy, and/or other interventions).
- HIGHLY PROBABLE
  - Reasonable temporal relation to vaccination, AND
  - Labeled/expected reaction, AND
  - The reaction cannot be reasonably explained by other factors (such as the subject's clinical state, concomitant therapy, and/or other interventions), AND
  - Positive de-challenge, if applicable, AND
  - Positive re-challenge, OR
  - Application/vaccination site reaction.

### 3 Definition of Reportable Events

The following adverse events are considered "serious reportable adverse events:"

- Death of a subject or life threatening events.
- Hospitalization (other than elective procedures or outpatient observation of <24 hour duration) or prolongation of hospitalization.
- Cancer or congenital anomaly.
- Chronic or permanent disability.
- Overdose.
- Any serious adverse event (i.e., an adverse event that is graded as serious or life-threatening in appendix 2).

## APPENDIX 2

### Table for Grading Severity of Adult Adverse Experiences for Vaccine Trials

#### Guidelines

ABBREVIATIONS: Abbreviations utilized in this Table include:

ULN	=Upper Limit of Normal	LLN	=Lower Limit of Normal
R <sub>x</sub>	=Therapy	Req	=Required
Mod	=Moderate	IV	=Intravenous
ADL	=Activities of Daily Living	Dec	=Decreased

#### ESTIMATING SEVERITY GRADE

For abnormalities NOT found elsewhere in the Toxicity Table use the scale below to estimate grade of severity:

GRADE 1	Mild	Transient or mild discomfort (< 48 hours); no medical intervention/therapy required.
GRADE 2	Moderate	Mild to moderate limitation in activity – some assistance may be needed; no or minimal medical intervention/therapy required.
GRADE 3	Severe	Marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospitalization possible.
GRADE 4	Life- threatening	Extreme limitation in activity, significant assistance required; significant medical intervention/therapy required, hospitalization or hospice care probable.

#### SERIOUS OR LIFE-THREATENING Adverse Events

ANY clinical event deemed by the clinician to be serious or life-threatening should be considered a Grade 4 Adverse Event. Clinical events considered to be serious or life-threatening include, but are not limited to: seizures, coma, tetany, diabetic ketoacidosis, disseminated intravascular coagulation, diffuse petechiae, paralysis, acute psychosis, severe depression.

#### MISCELLANEOUS

- When two values are used to define the criteria for each parameter, the lowest values will appear first.
- Parameters are generally grouped by body system.
- Some protocols may have additional protocol specific grading criteria.

APPENDIX 2 continued – Modified Table for Grading Severity of Adult Adverse Experiences  
for Vaccine Trials

Parameter	Grade 1 Mild	Grade 2 Moderate	Grade 3 Severe	Grade 4 Potentially Life-Threatening
POTASSIUM				
Hyperkalemia	5.0 – 5.5 meq/L	5.6 – 6.0 meq/L	6.1 – 6.5 meq/L	>6.5 meq/L
Hypokalemia	3.2 – 3.4 meq/L	2.9 – 3.1 meq/L	2.5 – 2.8 meq/L	<2.5 meq/L
PHOSPHATE				
Hypophosphatemia	2.0 – 2.4 mg/dL	1.5 – 1.9 mg/dL	1.0 – 1.4 mg/dL	<1.0 mg/dL
CALCIUM – (corrected for albumin)				
Hypocalcemia	7.8 – 8.4 mg/dL	7.0 – 7.7 mg/dL	6.1 – 6.9 mg/dL	<6.1 mg/dL
Hypercalcemia	10.6 – 11.5 mg/dL	11.6 – 12.5 mg/dL	12.6 – 13.5 mg/dL	>13.5 mg/dL
MAGNESIUM				
Hypomagnesemia	1.2 – 1.4 meq/L	0.9 – 1.1 meq/L	0.6 – 0.8 meq/L	<0.6 meq/L
BILIRUBIN				
Hyperbilirubinemia	>1.0 – 1.5 x ULN	>1.5 – 2.5 x ULN	>2.5 – 5 x ULN	>5 x ULN
GLUCOSE				
Hypoglycemia	55 - 84 mg/dL	40 – 54 mg/dL	30 -39 mg/dL	<30 mg/dL
Hyperglycemia (nonfasting and no prior diabetes)	118 – 160 mg/dL	161 - 250 mg/dL	251 – 500 mg/dL	>500 mg/dL
Triglycerides	----	400 - 750 mg/dL	751 – 1200 mg/dL	>1200 mg/dL
URIC ACID				
Hyperuricemia	7.5 – 10.0 mg/dL	10.1 – 12.0 mg/dL	12.1 – 15.0 mg/dL	>15.0 mg/dL
LIVER TRANS- AMINASE (LFTs)				
AST (SGOT)	1.25 – 2.5 x ULN	>2.5 – 5.0 x ULN	>5.0 – 10.0 x ULN	> 10.0 x ULN
ALT (SGPT)	1.25 – 3.0 x ULN	>3.0 – 5.0 x ULN	>5.0 – 10.0 x ULN	> 10.0 x ULN
GGT	1.25 – 2.5 x ULN	>2.5 – 5.0 x ULN	>5.0 – 10.0 x ULN	> 10.0 x ULN
Alk Phos	1.25 – 2.5 x ULN	>2.5 – 5.0 x ULN	>5.0 – 10.0 x ULN	> 10.0 x ULN
PANCREATIC ENZYMES				
Amylase	>1.0 – 1.5 x ULN	>1.5 – 2.0 x ULN	>2.0 – 5.0 x ULN	>5.0 x ULN
Pancreatic amylase	>1.0 – 1.5 x ULN	>1.5 – 2.0 x ULN	>2.0 – 5.0 x ULN	>5.0 x ULN
Lipase	>1.0 – 1.5 x ULN	>1.5 – 2.0 x ULN	>2.0 – 5.0 x ULN	>5.0 x ULN

APPENDIX 2 continued – Modified Table for Grading Severity of Adult Adverse Experiences  
for Vaccine Trials

Parameter	Grade 1 Mild	Grade 2 Moderate	Grade 3 Severe	Grade 4 Potentially Life-Threatening
CARDIOVASCULAR				
Cardiac Arrhythmia	-----	Asymptomatic; transient dysrhythmia, no R <sub>x</sub> req	Recurrent/persistent dysrhythmia; symptomatic R <sub>x</sub> req	Unstable dysrhythmia, hospitalization and R <sub>x</sub> req
Hypertension	Transient, increase >20 mm Hg diastolic BP; no R <sub>x</sub> req	Recurrent; chronic increase >20 mm Hg diastolic BP; R <sub>x</sub> req	Acute R <sub>x</sub> req; outpatient OR hospitalization possible	Hospitalization req OR end organ damage
Hypotension	Transient orthostatic hypotension with heart rate increased by >20 beats/min OR decreased by <10 mm Hg systolic BP, no R <sub>x</sub> req	Symptoms OR BP decreased by <20 mm Hg systolic, correctable with oral fluid R <sub>x</sub>	IV fluid req OR hospitalization	Mean arterial pressure <60 mm Hg, OR end organ damage, OR shock, vasopressor R <sub>x</sub> req
Pericarditis	Minimal effusion	Mild/mod asymptomatic effusion, no R <sub>x</sub>	Symptomatic effusion, pain, EKG changes	Tamponade OR pericardiocentesis OR surgery req
Hemorrhage, blood loss	-----	Mildly symptomatic, no R <sub>x</sub> req	Gross blood loss OR 1-2 units transfused	Massive blood loss OR >2 units transfused
GASTROINTESTINAL				
Nausea	Mild OR transient; reasonable intake maintained	Mod discomfort OR intake decreased for <3 days	Severe discomfort OR minimal intake for ≥3 days	Hospitalization req
Vomiting	Mild OR transient; 2-3 episodes per day OR mild vomiting lasting <1 week	Mod OR persistent; 4-5 episodes per day; OR vomiting lasting ≥ week	Severe vomiting of all food/fluids in 24 hrs OR orthostatic hypotension OR IV R <sub>x</sub> req	Hypotensive shock OR hospitalization req for IV R <sub>x</sub> req
Diarrhea	Mild OR transient; 3-4 loose stools per day OR mild diarrhea lasting <1 week	Mod OR persistent; 5-10 loose stools per day OR diarrhea lasting ≥1 week	>10 loose stools/day bloody diarrhea; OR orthostatic hypotension OR electrolyte imbalance, >2 L IV fluid req	Hypotensive shock OR severe electrolyte imbalance
Oral Discomfort/ Dysphagia	Mild discomfort, no difficulty swallowing	Difficulty swallowing but able to eat and drink	Unable to swallow solids	Unable to drink fluids; IV fluids req
Constipation	-----	Moderate abdominal pain 78 hours with impaction require outpatient prescription	Requiring disimpaction or hospital treatment	Distention with vomiting OR obstipation

**APPENDIX 2 – Modified Table for Grading Severity of Adult Adverse Experiences for Vaccine Trials**

Parameter	Grade 1 Mild	Grade 2 Moderate	Grade 3 Severe	Grade 4 Potentially Life-Threatening
Cough (for aerosol studies)	Transient; no R <sub>x</sub>	Treatment associated cough; inhaled bronchodilator	Uncontrolled cough; systemic R <sub>x</sub> req	-----
Bronchospasm Acute	Transient; no R <sub>x</sub> ; FEV1 or peak flow reduced to 70% - 80%	R <sub>x</sub> req; normalizes with bronchodilator; FEV1 or peak flow 50% - 69%	No normalization with bronchodilator; FEV1 or peak flow 25% - 49%, retractions	Cyanosis; FEV1 or peak flow <25% OR intubated
Dyspnea	Dyspnea on exertion	Dyspnea with normal activity	Dyspnea at rest	Dyspnea requiring O <sub>2</sub> therapy
<b>NEUROLOGICAL</b>				
Neuro-cerebellar	Slight incoordination OR Dysdiadochokinesia	Intention tremor OR dysmetria OR slurred speech OR nystagmus	Ataxia requiring assistance to walk or arm incoordination interfering with ADLs	Unable to stand
Neuro-psych/mood	-----	-----	Severe mood changes requiring medical intervention; suicidal ideation	Acute psychosis req hospitalization ; suicidal gesture/attempt
Parasthesia (burning, tingling, etc.)	Mild discomfort; no R <sub>x</sub> req	Mod discomfort; non-narcotic analgesia required	Severe discomfort; OR narcotic analgesia req with symptomatic improvement	Incapacitating; OR not responsive to narcotic analgesia
Neuro-motor	Mild weakness in muscle of feet but able to walk and/or mild increase or decrease in reflexes	Mod weakness in feet (unable to walk on heels and/or toes), mild weakness in hands, still able to do most hand tasks and/or loss of previously present reflex or development of hyperreflexia and/or unable to do deep knee bends to weakness	Marked distal weakness (unable to dorsiflex toes or foot drop, and mod proximal weakness e.g., in hands interfering with ADLs and/or requiring assistance to walk and/or unable to rise from chair unassisted	Confined to bed or wheel chair because of muscle weakness
Neuro-sensory	Mild impairment (decreased sensation, e.g., vibratory, pinprick, hot/cold in great toes) in focal area or symmetrical distribution	Mod impairment (mod decreased sensation, e.g., vibratory, pinprick, hot/cold to ankles) and/or joint position or mild impairment that is not symmetrical	Severe impairment (decreased or loss of sensation to knees or wrists) or loss of sensation of at least mod degree in multiple different body sites (i.e., upper and lower extremities)	Sensory loss involves limbs and trunk

APPENDIX 2 continued – Modified Table for Grading Severity of Adult Adverse Experiences  
for Vaccine Trials

Parameter	Grade 1 Mild	Grade 2 Moderate	Grade 3 Severe	Grade 4 Potentially Life-Threatening
Arthralgia/Arthritis	Arthralgia	Arthralgia with joint effusion or moderate impairment of activity	Frank arthritis with or without effusion OR resulting in severe impairment of activity	-----
Myalgia	Myalgia without limitation of activity	Muscle tenderness at other than injection site or with moderate impairment of activity	Frank myonecrosis OR with severe impairment of activity	-----
SKIN				
Skin (vaccination site)	Refer to Appendix 4 for evaluation of specific changes at site of vaccination			
Skin (general)	Scattered macular or papular eruption or erythema that is asymptomatic	Scattered macular or papular eruption or erythema with pruritus or other associated symptoms	Generalized symptomatic macular, papular, or vesicular eruption	Exfoliative dermatitis or ulcerating dermatitis
URINALYSIS				
Proteinuria: Random urine	1+	2 - 3+	4+	Nephrotic syndrome
Proteinuria: 24 hour urine	200 mg - 1 g loss/day OR <0.3% OR <3 g/l	1 – 2 g loss/day OR 0.3 – 1.0% OR 3 - 10 g/l	2 – 3.5 g loss/day OR >1.0% OR > 10 g/l	Nephrotic syndrome OR >3.5 g loss/day
Proteinuria: Hematuria	Microscopic only ≤10 RBC/HPF	>10 RBC/HPF	Gross, with or without clots OR RBC casts	Obstructive OR transfusion req

APPENDIX 2 continued – Modified Table for Grading Severity of Adult Adverse Experiences for Vaccine Trials

Parameter	Grade 1 Mild	Grade 2 Moderate	Grade 3 Severe	Grade 4 Potentially Life-Threatening
MISCELLANEOUS				
Fever Oral>12 hours	37.7 - 38.9°C (100.0 – 101.5°F)	39.0 – 39.5°C (101.6 – 102.9°F) OR max temp of 103°F	39.8 – 40.5°C (103 - 105°F) OR max temp of 103.5°F	>40.5°C (105°F) OR max temp of >105°F
Headache	Mild, no R <sub>x</sub> req, OR non-narcotic analgesia R <sub>x</sub>	Mod; OR responds to initial narcotic R <sub>x</sub>	Severe; intractable; OR requiring repeated narcotic R <sub>x</sub>	Requiring hospitalization, associated with neurologic, respiratory or cardiovascular abnormalities
Allergic Reaction	Pruritus without rash at injection site	Localized urticaria at injection site	Generalized urticaria angioedema	Anaphylaxis
ADL	Normal activity reduced <48 hours	Normal activity reduced 25 - 50% >48 hours	Normal activity reduced >50%; cannot work >48 hours	Unable to care for self
Eye		Mild pain, visual changes, conjunctival erythema, abnormal slit lamp	Loss of vision, clinically diagnosed uveitis, mod-severe pain, glaucoma	-----